Dimension Inx designs and develops therapeutic products that restore tissue and organ function. The company uses biomaterials and a manufacturing process to create products with design versatility and a nuanced microarchitecture for biofunctionality.

Dimension Inx

Dimension Inx is the architect of regenerative microenvironments. Our materials give the body a blueprint to heal itself. We take a materials-centric approach to solving patient needs. By creating structures that emulate the body’s microenvironment, we elicit an immediate regenerative response. 

We design for biofunctionality and manufacturability. Our platform is highly adaptable and not limited to any single material. Our collaborative studio approach allows us to co-create a lasting advantage by partnering with leading product and R&D organizations. Contact us to accelerate the development of new regenerative solutions today.

U.S. Department of Defense

Revolution’s Rise of the Rest Seed Fund

KdT Ventures

Better Ventures

Pathway Bioventures

Solas BioVentures

Alumni Ventures

Portal Innovations

Prime Movers Lab

Exciting news! Dimension Inx was named a finalist at Fast Company 2024 Innovation by Design Awards for our pioneering work developing CMFlex™!

CMFlex is a ready-to-use, flexible ceramic graft designed for bone reconstruction. It leverages a distinctive material microstructure and macroarchitecture for rapid vascularization and tissue integration to promote bone regeneration and remodeling, which can improve patient outcomes. To learn more about CMFlex, please visit https://www.cmflex3d.com/.

We’re proud and honored to be recognized alongside others solving the problems of today and tomorrow. Check out the full list of the best designs from small businesses: https://lnkd.in/g5HYNxRp. 

#FCDesignAwards #RegenerativeMedicine #CMFlex #ChicagoInnovation

Thanks for the shout-out, Desktop Health! We're grateful for the continued partnership.

We remain excited about this research program focused on using novel biomaterial scaffolds to drive follicular growth and maturation with our partners at Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University, especially our collaborator, Monica M. Laronda. 

#Bioprinting #RegenerativeMedicine #3DBioplotter #Biomaterials #ArtificialOvary #WomensHealth

We’re excited to share that we’ve launched a new website for CMFlex, the first FDA-cleared fully synthetic 3D-printed regenerative bone graft.

Our new website at www.cmflex3d.com provides detailed information about CMFlex's unique advantages, including its customizable fit, high porosity, and balanced flexibility and rigidity, designed for usability and to promote bone repair and regeneration.

We’re proud to be paving the way for a new generation of advanced biomaterials and encourage you to check out the new website!

#CMFlex #3dprinting #oralsurgery #dimensioninx #oralmaxillofacialsurgery #hydroxyapatite #bonegraft

We are excited to announce the recent issuance of Dimension Inx’s newest patent, US Patent No. 11,944,726, which covers the composition and manufacture of a novel, hydrogel-containing material family that is shelf-stable in its dry form, yet forms an interconnected gel network when hydrated, i.e., it’s “self-gelling”.
 
This material family is unique because it enables the creation of 3D-printable, gel-laden, nanostructured implants and #injectables that combine the biofunctional nano- and #microstructure characteristics of our biomaterials with the additional biological benefits of hydrogels. It also offers an innovative and simple approach to the delivery, localization, and stabilization of one or more hydrogels in vivo. It’s yet another demonstration of our platform’s unique capabilities - simultaneous control of material architecture and composition to promote cell viability and tissue engraftment while maintaining manufacturability and user-friendliness.

Thanks to our co-founder, Adam Jakus, Ph.D., who strategically developed this technology in response to existing limitations in the delivery and localization of hydrogel-based biomaterials. This work further expands upon an expansive patent portfolio at Dimension Inx beyond implantable materials to include injectables – all of which are dedicated to the design and manufacture of advanced #biomaterials for #tissuetherapeutic products that rebuild healthy tissues and restore organ function.

To learn more about our technology or if you're interested in joining a motivated team developing the next generation of regenerative therapeutics, please visit https://lnkd.in/d5ttjxk8.

We are excited to announce the recent issuance of two patents, U.S. Patent No. 11,896,740, which covers the manufacture of our highly tunable and porous Fluffy-X™ material family, and U.S. Patent No. 11,904,071, which covers the manufacture and use of our decellularized ECM-based Tissue Papers™ material family.
 
These material families highlight our platform’s unique capabilities - the control of both material structure and composition without compromising the ability to form complex constructs that demonstrate excellent handling properties and mechanical integrity. Our approach to the design and manufacture of advanced biomaterials for #tissuetherapeutic applications emphasizes the cellular and tissue microenvironment. We embrace the complex interplay between biology, material composition, microstructure, and macroarchitecture to direct optimal cell behavior and to create #regenerativemedicine products that rebuild healthy tissues and restore organ function.

Shout out to our co-founders, Ramille S., Ph.D. and Adam Jakus, Ph.D., who co-developed these technologies from nearly a decade of research at Northwestern University’s Tissue Engineering and Additive Manufacturing Lab. We are continuing to expand upon their foundation and advance our patent portfolio at Dimension Inx.

To learn more about our technology or if you're interested in joining an motivated team developing the next generation of tissue therapeutics, please visit https://lnkd.in/d5ttjxk8.

📣 Exciting News! Last week Dimension Inx was awarded Honorable Mention at the 2023 3D Printing Industry Awards in the category of Medical, Dental, or Health Application. We are grateful for this recognition celebrating our first product, CMFlex™, being used in patients. This achievement marks a notable advancement for 3D-printed medical applications, and we are honored to be included among all the outstanding nominees. A big thank you 🙏  to our team for their relentless effort that continues to drive our success. 🚀 

Also, a special congratulations to the category winner, Stratasys!

#3dprinting #additivemanufacturing #healthcareinnovation

https://lnkd.in/g9ZaEJdm

Thank you for sharing our story, Desktop Health! We're thrilled about our recent clinical launch of CMFlex™, the first 3D-printed regenerative bone graft product cleared by the FDA. 

We wouldn't be here without partners like you. Onwards and upwards.

#BiomedicalInnovation #Bioprinting #HealthcareInnovation #DesktopHealth #3DBioplotter #3DPrinting #MedicalInnovation

We are thrilled to announce the first patient use of CMFlex™, the FIRST FDA-cleared 3D-printed regenerative bone graft product. This huge milestone would not have been possible without the dedication and unwavering support of our exceptional team, visionary investors, and steadfast partners. We extend our heartfelt gratitude and admiration for their support and trust throughout this journey.

In these first-in-human surgeries, performed by distinguished surgeons Dr. Derek Steinbacher, Dr. Brian Farrell, and Dr. Robert Bosack, CMFlex has demonstrated its potential to positively impact patient lives.

This remarkable milestone underscores our commitment to advancing the field of regenerative medicine, with CMFlex paving the way for innovative solutions for patients. We are immensely proud of this achievement and look forward to a future filled with possibilities and groundbreaking discoveries.

#DimensionInx #CMFlex #RegenerativeMedicine #Innovation #Biotechnology #MedicalAdvancements

https://lnkd.in/g2bYAsXb

10 days until Alliance for Regenerative Medicine’s #CGMesa23! Our team looks forward to connecting with senior executives and top stakeholders Oct 10-12 to tackle the most pressing issues in cell and gene therapies. Send us a partnering request to explore how we use our 3D-printed biomaterials platform to develop #regenerative therapeutics that boost cell viability and engraftment. 
Learn more: https://lnkd.in/eiUpMy4

Pound Sterling

Squarespace Hosted

Chief Technology Officer and Co-Founder

Adam Jakus

Chief Executive Officer

Caralynn Collens

Co-Founder & CEO

Chief Operating Officer

Dan Dodd

Chief Scientific Officer

Ramille Shah

Vice President, Strategic Growth

Cole Johnson

SVP, Product

Henry Kim

Engineering

Jinwhan Lee, PhD

Director of Operations

Matthew Opad

Director of Strategy & Business Development

Robert Awh

Amy Kruse

Caralynn Nowinski Collens

CEO and Co-Founder

Co-Founder and CTO

Co-Founder and CSO

Chicago Companies With Fewer Than 50 Employees (Top 10K)

3D Printing Companies With Less Than $1B in Revenue

Therapeutics Female Founded Companies with Early Stage Venture Funding

United States Startups (Top 10K)

Dimension Inx specializes in developing regenerative microenvironments that give the body a blueprint to heal itself. Its biomaterials platform embraces the complex interplay between material composition, microstructure, and microarchitecture to produce biofunctionality within the body.

The company was founded in 2017 and is headquartered in Chicago, Illinois.

Series A - Dimension Inx

Venture Round - Dimension Inx

Grant - Dimension Inx

Seed Round - Dimension Inx

Chicago

Illinois

United States

North America

The best designs of 2024 from small businesses

Food and Drug Administration

Why Dimension Inx co-founder Adam Jakus left to launch a biotech consulting firm

Why Dimension Inx co-founder Adam Jakus left to launch a biotech consulting firm - Chicago Business Journal

news impact assignment basic	general
public peers	general	Sep 4, 2024 6:22 AM	b3ec2092
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 8:01 AM	4b47639a
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	eeda0c4e
crunchbase profile	general	Oct 31, 2024 3:43 AM	326ec252
li profile	general	Sep 4, 2024 6:22 AM	151bcf06
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	30e49f37
peers	general	Sep 4, 2024 6:22 AM	29f468f5
news basic	general	Sep 4, 2024 6:22 AM	76a53a9c
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

DIME

COM:DIMENSIONINX

Dimension Inx